178 related articles for article (PubMed ID: 26191041)
1. IGF-1 Receptor and Adhesion Signaling: An Important Axis in Determining Cancer Cell Phenotype and Therapy Resistance.
Cox OT; O'Shea S; Tresse E; Bustamante-Garrido M; Kiran-Deevi R; O'Connor R
Front Endocrinol (Lausanne); 2015; 6():106. PubMed ID: 26191041
[TBL] [Abstract][Full Text] [Related]
2. Essential function for PDLIM2 in cell polarization in three-dimensional cultures by feedback regulation of the β1-integrin-RhoA signaling axis.
Deevi RK; Cox OT; O'Connor R
Neoplasia; 2014 May; 16(5):422-31. PubMed ID: 24863845
[TBL] [Abstract][Full Text] [Related]
3. Insulin-like growth factor 1 is a potent stimulator of cervical cancer cell invasiveness and proliferation that is modulated by alphavbeta3 integrin signaling.
Shen MR; Hsu YM; Hsu KF; Chen YF; Tang MJ; Chou CY
Carcinogenesis; 2006 May; 27(5):962-71. PubMed ID: 16400188
[TBL] [Abstract][Full Text] [Related]
4. The insulin-like growth factor type 1 receptor and colorectal neoplasia: insights into invasion.
Allison AS; McIntyre MA; McArdle C; Habib FK
Hum Pathol; 2007 Nov; 38(11):1590-602. PubMed ID: 17651787
[TBL] [Abstract][Full Text] [Related]
5. The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
Chen B; Xiao F; Li B; Xie B; Zhou J; Zheng J; Zhang W
Cancer Invest; 2013 Aug; 31(7):454-60. PubMed ID: 23915069
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.
Nair PN; De Armond DT; Adamo ML; Strodel WE; Freeman JW
Oncogene; 2001 Dec; 20(57):8203-14. PubMed ID: 11781836
[TBL] [Abstract][Full Text] [Related]
8. Extracellular matrix density promotes EMT by weakening cell-cell adhesions.
Kumar S; Das A; Sen S
Mol Biosyst; 2014 Apr; 10(4):838-50. PubMed ID: 24481128
[TBL] [Abstract][Full Text] [Related]
9. IGF/STAT3/NANOG/Slug Signaling Axis Simultaneously Controls Epithelial-Mesenchymal Transition and Stemness Maintenance in Colorectal Cancer.
Yao C; Su L; Shan J; Zhu C; Liu L; Liu C; Xu Y; Yang Z; Bian X; Shao J; Li J; Lai M; Shen J; Qian C
Stem Cells; 2016 Apr; 34(4):820-31. PubMed ID: 26840943
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Bodzin AS; Wei Z; Hurtt R; Gu T; Doria C
J Cell Physiol; 2012 Jul; 227(7):2947-52. PubMed ID: 21959795
[TBL] [Abstract][Full Text] [Related]
11. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis.
Bagnato A; Rosanò L
Cells Tissues Organs; 2007; 185(1-3):85-94. PubMed ID: 17587812
[TBL] [Abstract][Full Text] [Related]
12. Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M; Emami S; Redeuilh G; Julien S; Prévost G; Zimber A; Ouelaa R; Bracke M; De Wever O; Gespach C
Drug Resist Updat; 2008; 11(4-5):123-51. PubMed ID: 18718806
[TBL] [Abstract][Full Text] [Related]
13. EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Maslova K; Kyriakakis E; Pfaff D; Frachet A; Frismantiene A; Bubendorf L; Ruiz C; Vlajnic T; Erne P; Resink TJ; Philippova M
FASEB J; 2015 Feb; 29(2):494-507. PubMed ID: 25381040
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
15. Targeting IGF-1 signaling pathways in gynecologic malignancies.
Bruchim I; Werner H
Expert Opin Ther Targets; 2013 Mar; 17(3):307-20. PubMed ID: 23294364
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of IGF-1 signaling by genistein: modulation of E-cadherin expression and downregulation of β-catenin signaling in hormone refractory PC-3 prostate cancer cells.
Lee J; Ju J; Park S; Hong SJ; Yoon S
Nutr Cancer; 2012; 64(1):153-62. PubMed ID: 22098108
[TBL] [Abstract][Full Text] [Related]
17. Growth differentiation factor 15 mediates epithelial mesenchymal transition and invasion of breast cancers through IGF-1R-FoxM1 signaling.
Peake BF; Eze SM; Yang L; Castellino RC; Nahta R
Oncotarget; 2017 Nov; 8(55):94393-94406. PubMed ID: 29212236
[TBL] [Abstract][Full Text] [Related]
18. Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.
Kim JS; Lee SC; Min HY; Park KH; Hyun SY; Kwon SJ; Choi SP; Kim WY; Lee HJ; Lee HY
Cancer Lett; 2015 Jun; 361(2):197-206. PubMed ID: 25721083
[TBL] [Abstract][Full Text] [Related]
19. OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.
Rao W; Li H; Song F; Zhang R; Yin Q; Wang Y; Xi Y; Ge H
Carcinogenesis; 2014 Jul; 35(7):1573-81. PubMed ID: 24667688
[TBL] [Abstract][Full Text] [Related]
20. Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells.
Plymate SR; Bae VL; Maddison L; Quinn LS; Ware JL
Endocrinology; 1997 Apr; 138(4):1728-35. PubMed ID: 9075737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
